If one, for example, were to simply give an AQP4 blocker to stroke patients, timing would be critical; if given too early, it might reduce cytotoxic edema and tissue damage, but if continued too long, it could impair later edema clearance, worsening outcomes and becoming potentially fatal. This evidence concerns the gene AQP4 and stroke disorder.